Skip to main content

Table 2 Clinical trials and preclinical evaluations on Wnt/β-catenin targeted agents in hematological malignancies

From: Targeting the Wnt/β-catenin signaling pathway in cancer

Agents Mechanism Phase Cancer type Side effects Identifier
CWP291 SAM68 inhibitor Phase 1 Relapsed or refractory AML and MDS Nausea, vomiting, diarrhea, and infusion-related reactions NCT01398462
PRI-724 CBP/β-catenin antagonist Phase 2 AML; CML NR NCT01606579
GNE-781 CBP antagonist Preclinical AML
ICG001 CBP antagonist Preclinical AML; ALL; CML; MM
WNT974 PORCN inhibitor Preclinical BL  
Wnt-C59 PORCN inhibitor Preclinical cHL  
IWP-2/IWP-4 PORCN inhibitor Preclinical AML; cHL  
XAV939 Tankyrase inhibitor Preclinical AML; T-ALL; CML  
IWR-1 Tankyrase inhibitor Preclinical APL  
Salinomycin LRP5/6 inhibitor Preclinical CLL; MCL  
iCRT14 β-catenin/TCF Preclinical ALL; MCL